Hemophilia A trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Hemophilia A. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month3 studies across 2 companies, in the next 180 days.
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NVO | Novo Nordisk A/S | Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in GermanyNCT07653139observationalChoice of treatment alternative in discrete choice tasks | — | Not yet recruiting | 2026-10-26 | in 67 d | 2026-06-17 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SOBI.ST | Swedish Orphan Biovitrum | A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa ProphylaxisNCT06752850Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) synovial hypertrophy domain score decrease. | Phase 4 | Active, not recruiting | 2026-11-17 | in 89 d | 2026-04-30 |
February 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NVO | Novo Nordisk A/S | A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia ANCT07220564Number of treatment emergent adverse events | Phase 1 | Recruiting | 2027-02-05 | in 169 d | 2026-08-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Hemophilia A
most recently updated first154 studies match. Showing the first 100 of 154 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | Pfizer | $155.3B | Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A AdultsNCT04370054results2025-08-17Total Annualized Bleeding Rate (ABR) | Phase 3 | Active, not recruiting | Biological: PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy | Hemophilia A | 77 | 2020-08-18 | 2024-06-17actual | — | 2026-08-19 |
| PFE | Pfizer | $155.3B | Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia BNCT03938792results2026-08-14Model-Based Annualized Bleeding Rate (ABR) of Treated Bleeding Events: Inhibitor Cohort (Participants With Prior OD Therapy at OP) | Phase 3 | Completed | Drug: PF-06741086 | Hemophilia A, Hemophilia B | 188 | 2020-03-09 | 2025-04-29actual | — | 2026-08-14 |
| PFE | Pfizer | $155.3B | A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BNCT05611801Annualized bleeding rate (ABR) of treated bleeding events | Phase 3 | Recruiting | Drug: marstacimab | Hemophilia A, Hemophilia B | 100 | 2022-12-09 | 2028-09-10 | in 752 d | 2026-08-10 |
| NVO | Novo Nordisk A/S | — | A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia ANCT07220564Number of treatment emergent adverse events | Phase 1 | Recruiting | Drug: NNC0442-0344 A | Haemophilia A | 30 | 2025-10-23 | 2027-02-05 | in 169 d | 2026-08-10 |
| BMRN | BioMarin Pharmaceutical | $13.0B | Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior InhibitorsNCT04684940Number of participants with treatment-related adverse events, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 after administration of BMN 270. | Phase 1/2 | Completed | Biological: Valoctocogene roxaparvovec | Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII | 10 | 2020-12-10 | 2026-04-20actual | — | 2026-07-10 |
| PFE | Pfizer | $155.3B | Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsNCT05145127Number of subject reporting Adverse Events | Phase 3 | Recruiting | Drug: PF-06741086 | Hemophilia A, Hemophilia B | 245 | 2021-11-17 | 2030-07-31 | in 1,441 d | 2026-07-01 |
| NVO | Novo Nordisk A/S | — | A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia ANCT05685238Arm 1 and 2: Number of treatment emergent adverse events | Phase 3 | Recruiting | Drug: Mim8 | Haemophilia A, Haemophilia A With Inhibitors | 451 | 2023-02-13 | 2028-06-30 | in 680 d | 2026-06-30 |
| SOBI.ST | Swedish Orphan Biovitrum | — | Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaNCT06940830Annualized joint bleeding rate (AjBR) over the prospective observation period. | Phase 4 | Recruiting | Drug: Efanesoctocog alfa | Hemophilia A | 250 | 2025-05-21 | Dec 2028 | ≤ 864 d | 2026-06-30 |
| SOBI.ST | Swedish Orphan Biovitrum | — | Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog AlfaNCT06716814Number of injections to treat a bleeding episode | Phase 3 | Recruiting | Drug: Efanesoctocog alfa | Haemophilia A (Moderate or Severe) | 104 | 2025-03-06 | Mar 2027 | ≤ 223 d | 2026-06-26 |
| SOBI.ST | Swedish Orphan Biovitrum | — | Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ANCT06579144Half-life (t½) of efanesoctocog alfa, damactocog alfa pegol and turoctocog alfa pegol after a single i.v. injection | Phase 1 | Completed | Drug: Efanesoctocog alfa | Hemophilia A | 24 | 2025-02-24 | 2026-05-21actual | — | 2026-06-25 |
| NVO | Novo Nordisk A/S | — | Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A PatientsNCT06574984observationalAnnual bleeding Rate (ABRs) among patients treated with different regimen of turoctocog alfa after previous FVIII replacement therapy | — | Completed | Drug: Turoctocog alfa | Congenital Bleeding Disorder, Haemophilia A | 329 | 2024-11-10 | 2025-11-04actual | — | 2026-06-17 |
| NVO | Novo Nordisk A/S | — | A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy PeopleNCT07238816AUC0-∞: the area under the plasma Inno8 concentration-time curve from time 0 to infinity after a single oral dose | Phase 1 | Completed | Drug: NNC0442-0344 A | Haemophilia A | 80 | 2025-11-18 | 2026-05-08actual | — | 2026-06-17 |
| NVO | Novo Nordisk A/S | — | Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in GermanyNCT07653139observationalChoice of treatment alternative in discrete choice tasks | — | Not yet recruiting | Other: No treatment given | Haemophilia A | 150 | 2026-07-10 | 2026-10-26 | in 67 d | 2026-06-17 |
| NVO | Novo Nordisk A/S | — | Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®NCT04334057observationalNumber of adverse reactions (ARs) reported during the observation period | — | Completed | Drug: Turoctocog alfa pegol | Haemophilia A | 23 | 2021-03-31 | 2023-11-30actual | — | 2026-06-15 |
| NVO | Novo Nordisk A/S | — | Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With InhibitorsNCT06285071observationalNumber of adverse reaction (AR) | — | Enrolling by invitation | Drug: Concizumab | Haemophilia A, Haemophilia B | 23 | 2024-08-08 | 2030-04-30 | in 1,349 d | 2026-06-15 |
| NVO | Novo Nordisk A/S | — | Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With InhibitorsNCT04083781results2025-04-27Rate of Treated Spontaneous and Traumatic Bleeding Episodes | Phase 3 | Active, not recruiting | Drug: Concizumab | Haemophilia A With Inhibitors, Haemophilia B With Inhibitors | 134 | 2019-10-21 | 2021-12-27actual | — | 2026-06-12 |
| SNY | Sanofi | — | A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With EmicizumabNCT06145373Number of participants with Adverse events (AEs) during the fitusiran treatment | Phase 4 | Recruiting | Drug: Fitusiran (SAR439774) · Biological: Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC), Emicizumab | Hemophilia A | 20 | 2024-03-01 | 2028-05-28 | in 647 d | 2026-06-02 |
| PFE | Pfizer | $155.3B | Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B RespectivelyNCT05568719Incidence of thromboembolic events | Phase 3 | Recruiting | Diagnostic test: Testing of hepatic AAV Vector integration | Hemophilia A, Hemophilia B | 173 | 2022-12-28 | 2040-02-25 | in 4,937 d | 2026-05-27 |
| SOBI.ST | Swedish Orphan Biovitrum | — | A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa ProphylaxisNCT06752850Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) synovial hypertrophy domain score decrease. | Phase 4 | Active, not recruiting | Drug: Efanesoctocog alfa | Haemophilia A (Moderate or Severe), Hemophilia, Classic, Haemophilia, Hemophilia, Classic Hemophilia, Synovial Hypertrophy | 37 | 2024-12-19 | 2026-11-17 | in 89 d | 2026-04-30 |
| NVO | Novo Nordisk A/S | — | A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy MenNCT06649630SAD: Number of treatment emergent adverse events | Phase 1 | Completed | Drug: NNC0442-0344 A, Placebo | Haemophilia A | 95 | 2024-09-23 | 2026-03-26actual | — | 2026-04-01 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.NCT07161687observationalNumber of the participants with adverse drug reactions | — | Active, not recruiting | Drug: Marstacimab | Hemophilia A or B | 50 | 2025-10-30 | 2030-04-11 | in 1,330 d | 2026-03-30 |
| SOBI.ST | Swedish Orphan Biovitrum | — | A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint HealthNCT04293523observationalJoint health: Target joint development | — | Active, not recruiting | Drug: ELOCTA | Hemophilia A | 427 | 2020-03-30 | Jul 2026 | — | 2026-03-19 |
| BMRN | BioMarin Pharmaceutical | $13.0B | Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia ANCT06224907Change in the human coagulation factor VIII (hFVIII) activity, as measured by chromogenic substrate assay, during Weeks 49 to 52 post BMN 270 infusion from Baseline. | Phase 3 | Active, not recruiting | Biological: Valoctocogene roxaparvovec | Hemophilia A | 6 | 2023-12-25 | 2025-04-16actual | — | 2026-03-19 |
| SNY | Sanofi | — | Goal Attainment and Physical Activity in People With Hemophilia ANCT06530030observationalProportion of total goals achieved | — | Terminatedsponsor's stated reason: Early discontinuation based on sponsor decision not driven by any safety concerns. | Drug: efanesoctocog alfa | Hemophilia A | 3 | 2024-11-26 | 2025-09-18actual | — | 2026-01-20 |
| BMRN | BioMarin Pharmaceutical | $13.0B | A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)NCT05768386observationalEvaluate the long-term safety of BMN 270 | — | Enrolling by invitation | — | Hemophilia A | 172 | 2023-01-01 | Jan 2040 | ≤ 4,912 d | 2026-01-12 |
| NVO | Novo Nordisk A/S | — | Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)NCT05082116results2024-01-18Number of Bleeding Episodes Per Year (Annualised Bleeding Rate) | Phase 3 | Completed | Drug: turoctocog alfa pegol (N8-GP) | Haemophilia A | 36 | 2021-09-27 | 2022-12-28actual | — | 2026-01-06 |
| NVO | Novo Nordisk A/S | — | Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia ANCT02137850results2024-10-31Number of Participants With Inhibitory Antibodies Against Coagulation Factor VIII (FVIII) | Phase 3 | Completed | Drug: turoctocog alfa pegol | Congenital Bleeding Disorder, Haemophilia A | 124 | 2014-06-26 | 2023-06-07actual | — | 2025-12-23 |
| NVO | Novo Nordisk A/S | — | A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®NCT04574076observationalNumber of Adverse Events (AEs) reported during the study period | — | Enrolling by invitation | Drug: Turoctocog alfa pegol (N8-GP) | Haemophilia A | 60 | 2020-10-23 | 2027-06-03 | in 287 d | 2025-12-22 |
| NVO | Novo Nordisk A/S | — | A Research Study Investigating Mim8 in People With Haemophilia ANCT04204408Part 1: Number of treatment emergent adverse events | Phase 2 | Completed | Drug: NNC0365-3769 (Mim8), Placebo (Mim8) | Healthy Volunteers, Haemophilia A With or Without Inhibitors | 275 | 2020-01-10 | 2023-10-06actual | — | 2025-12-19 |
| NVO | Novo Nordisk A/S | — | A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without InhibitorsNCT05053139Number of treated bleeds | Phase 3 | Completed | Drug: NNC0365-3769 (Mim8) | Haemophilia A, Haemophilia A With Inhibitors | 281 | 2021-12-02 | 2024-03-11actual | — | 2025-12-08 |
| NVO | Novo Nordisk A/S | — | A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)NCT05878938Number of treatment-emergent adverse events | Phase 3 | Completed | Drug: NNC0365-3769 (Mim8) PPX | Haemophilia A, Haemophilia A With Inhibitors | 61 | 2023-06-26 | 2024-07-18actual | — | 2025-12-08 |
| NVO | Novo Nordisk A/S | — | A Research Study Looking at Mim8 in Children With Haemophilia A With or Without InhibitorsNCT05306418Number of treatment emergent adverse events | Phase 3 | Completed | Drug: Mim8 | Haemophilia A With or Without Inhibitors | 70 | 2022-04-04 | 2024-11-13actual | — | 2025-11-13 |
| PFE | Pfizer | $155.3B | A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)NCT03587116results2025-11-06Annualized Bleeding Rate (ABR) for Treated Bleeds and All Bleeds During Prospective Data Collection Period in Hemophilia B Participants: Efficacy Analysis Set | Phase 3 | Completed | Drug: Standard of Care FIX Replacement therapy, Standard of Care FVIII Replacement therapy | Hemophilia B, Hemophilia A | 212 | 2018-07-26 | 2024-12-13actual | — | 2025-11-06 |
| NVO | Novo Nordisk A/S | — | A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and CartridgeNCT05681845AUC0-112 days, SD: area under the Mim8 plasma concentration-time curve from time 0 until 112 days after a single dose | Phase 1 | Completed | Drug: NNC0365-3769 (Mim8) | Haemophilia A | 205 | 2023-01-02 | 2023-10-13actual | — | 2025-10-14 |
| BMRN | BioMarin Pharmaceutical | $13.0B | Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia ANCT04323098results2024-04-04Change From Baseline in FVIII Activity as Measured by Chromogenic Substrate Assay at Week 52. | Phase 3 | Completed | Biological: valoctocogene roxaparvovec | Hemophilia A | 22 | 2020-12-08 | 2023-01-27actual | — | 2025-10-08 |
| SNY | Sanofi | — | A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia ANCT05911763observationalChange from baseline in Annualized joint bleeding rate (AjBR) for treated bleeds | — | Active, not recruiting | Drug: Efanesoctocog Alfa BIVV001 | Hemophilia A | 200 | 2023-06-30 | 2028-06-06 | in 656 d | 2025-10-02 |
| SNY | Sanofi | — | A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanNCT06684314observationalChange from baseline in total scores of the Hemophilia Joint Health Score (HJHS) for all joints | — | Recruiting | Drug: Efanesoctocog alfa | Hemophilia A | 100 | 2024-11-11 | 2031-08-28 | in 1,834 d | 2025-10-02 |
| PFE | Pfizer | $155.3B | A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia ANCT03061201results2025-09-30Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 2 | Completed | Biological: SB-525 (PF-07055480) | Hemophilia A | 13 | 2017-06-21 | 2024-07-16actual | — | 2025-09-30 |
| NVO | Novo Nordisk A/S | — | Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa PegolNCT04682145observationalAdverse events (AEs) reported to the registry with suspected relation to turoctocog alfa pegol, Adverse Drug Reactions (ADRs), in patients with haemophilia A for renal, hepatic and neurological events. | — | Enrolling by invitation | Drug: Turoctocog alfa pegol | Haemophilia A | 50 | 2020-12-09 | 2026-02-01 | — | 2025-09-25 |
| SNY | Sanofi | — | Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia ANCT05042440Half-life of BIVV001 | Phase 1 | Completed | Drug: Efanesoctocog alfa, Octocog alfa, Rurioctocog alfa pegol | Hemophilia A | 13 | 2021-08-11 | 2021-11-24actual | — | 2025-09-18 |
| PFE | Pfizer | $155.3B | Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & BNCT06634836observationalFrequency of self-reported symptoms pre and post hemophilia gene therapy | — | Withdrawnsponsor's stated reason: Business decision | — | Hemophilia A, Hemophilia B | 0 | 2025-03-17 | 2025-12-31 | — | 2025-08-29 |
| BMRN | BioMarin Pharmaceutical | $13.0B | Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5NCT03520712results2025-08-22Number of Participants With Treatment Emergent Adverse Events | Phase 1/2 | Terminatedsponsor's stated reason: Early rollover into long-term extension study | Biological: Valoctocogene Roxaparvovec | Hemophilia A, Gene Therapy, Clotting Disorders, Blood Disorder | 3 | 2018-04-24 | 2024-08-07actual | — | 2025-08-22 |
| PFE | Pfizer | $155.3B | Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort StudyNCT02740413results2019-05-03observationalAge of Participants at Disease Diagnosis | — | Completed | — | Hemophilia A, Hemophilia B | 86 | 2016-01-11 | 2017-12-31actual | — | 2025-07-16 |
| PFE | Pfizer | $155.3B | Study Evaluating On-Demand Treatment Of Xyntha In Chinese SubjectsNCT00868530results2011-02-08Investigator Hemostatic Efficacy Assessment 8 Hours Post Infusion | Phase 3 | Completed | Biological: Xyntha | Hemophilia A | 53 | Sep 2008 | Dec 2009actual | — | 2025-06-12 |
| NVO | Novo Nordisk A/S | — | An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine EsperoctNCT05621746observationalChange in haemophilia joint health score (HJHS) | — | Recruiting | Drug: Esperoct | Haemophilia A | 100 | 2022-11-23 | 2026-06-30 | — | 2025-06-02 |
| BMRN | BioMarin Pharmaceutical | $13.0B | Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)NCT03370913results2023-11-28Change From Baseline in Annualized Number of Bleeding Episodes Irrespective of Exogenous FVIII Replacement Treatment [Annualized Bleeding Rate (ABR) for All Bleeds] in EEP. | Phase 3 | Completed | Biological: valoctocogene roxaparvovec | Hemophilia A | 144 | 2017-12-19 | 2020-11-16actual | — | 2025-03-25 |
| SOBI.ST | Swedish Orphan Biovitrum | — | An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog AlfaNCT05856266results2025-01-16Change From Baseline in Total HEAD-US Score up to Month 18 (End of Study - EOS) | Phase 4 | Terminatedsponsor's stated reason: The Sponsor has decided to stop the phase 4 study Sobi.HAEM89-007 (JOIN-us) due to a realignment of its development activities. The clinical trial hasn't been terminated due to a change in the benefit-risk balance. | Procedure: Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) · Other: Haemophilia Joint Health Score (HJHS) | Hemophilia A, Hemophilia B | 10 | 2023-08-24 | 2023-12-06actual | — | 2025-01-16 |
| SOBI.ST | Swedish Orphan Biovitrum | — | Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor ProductsNCT02976753observationalAnnualised bleeding rate (ABR) | — | Completed | Drug: efmoroctocog alfa, Factor VIII | Hemophilia A | 361 | Dec 2016 | 2021-11-03actual | — | 2024-10-02 |
| SOBI.ST | Swedish Orphan Biovitrum | — | A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or BNCT03055611observationalAnnualised bleeding rate (ABR) | — | Completed | Drug: ELOCTA, ALPROLIX | Haemophilia A, Haemophilia B | 201 | 2017-05-09 | 2022-04-19actual | — | 2024-10-02 |
| SOBI.ST | Swedish Orphan Biovitrum | — | Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI TherapiesNCT03103542results2021-11-30ITI Success | Phase 4 | Completed | Biological: Recombinant coagulation factor (rFVIIIFc) | Hemophilia A | 16 | 2017-08-29 | 2019-09-04actual | — | 2024-09-19 |
| SOBI.ST | Swedish Orphan Biovitrum | — | rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia ANCT03951103observationalITI with rFVIIIFc: Main dose | — | Completed | Other: rFVIIIFc | Hemophilia A With Inhibitor | 44 | 2018-11-07 | 2022-09-30actual | — | 2024-09-19 |
| SOBI.ST | Swedish Orphan Biovitrum | — | Impact on French Physician's Haemophilia Treatment Management Decision Based on Systematic Joint ExaminationNCT04133883Changes in haemophilia management based on systematic joint examinations of ankles, knees and elbows with HJHS and HEAD-US | Not applicable | Completed | Procedure: Ultrasound, Haemophilia Joint Health Score | Hemophilia A | 88 | 2020-01-13 | 2022-07-13actual | — | 2024-09-19 |
| SOBI.ST | Swedish Orphan Biovitrum | — | Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)NCT04731701observationalPsychometric validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST). | — | Completed | Diagnostic test: Hemophilia Joint Health Score (HJHS) | Hemophilia A, Hemophilia B | 180 | 2021-05-05 | 2022-07-19actual | — | 2024-09-19 |
| LLY | Eli Lilly and Company | $1.15T | Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia ANCT04541628results2024-09-04Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 1/2 | Terminatedsponsor's stated reason: SIG-001 programme terminated | Combination product: SIG-001 | Hemophilia A | 3 | 2020-09-28 | 2022-10-28actual | — | 2024-09-04 |
| BMRN | BioMarin Pharmaceutical | $13.0B | A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)NCT05580692To qunatify Seroprevalence of antibodies to selected AAV serotypes | Not applicable | Terminatedsponsor's stated reason: Sponsor decision to terminate; sufficient sample size for statistical analysis has been achieved. | Procedure: Biospecimen Collection | Hemophilia A | 321 | 2023-03-14 | 2024-07-31actual | — | 2024-08-19 |
| BMRN | BioMarin Pharmaceutical | $13.0B | A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia ANCT04560933observationalAssess the Seroprevalence of antibodies to AAV vectors in patients with hemophilia A | — | Completed | Procedure: Blood sample collection | Hemophilia A | 186 | 2020-08-25 | 2023-09-20actual | — | 2024-04-24 |
| SOBI.ST | Swedish Orphan Biovitrum | — | Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and BNCT03276130observationalUse of medication for pain, depression and anxiety (yes/no?) | — | Completed | — | Haemophilia A, Haemophilia B | 2,300 | 2018-10-30 | 2020-01-30actual | — | 2024-03-06 |
| NVO | Novo Nordisk A/S | — | Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major SurgeryNCT01561391Presence and maintenance of haemostasis | Phase 4 | Completed | Drug: activated recombinant human factor VII, activated recombinant human factor VII, factor VIII · Other: factor IX | Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors | 36 | Apr 1998 | May 2004actual | — | 2023-12-29 |
| NVO | Novo Nordisk A/S | — | A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With InhibitorsNCT01830712observationalLong-term changes in general mobility/ambulation/activity | — | Completed | Drug: eptacog alfa (activated) | Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors | 15 | Apr 2011 | Aug 2011actual | — | 2023-12-29 |
| NVO | Novo Nordisk A/S | — | Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational ActivitiesNCT04584892observationalIndividual prophylaxis (PPX) regimen with turoctocog alfa: Every second day, or three times a week (3TW), or twice a week (2TW) | — | Completed | Drug: Turoctocog alfa | Haemophilia A | 18 | 2021-04-12 | 2023-03-27actual | — | 2023-11-28 |
| BMRN | BioMarin Pharmaceutical | $13.0B | Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kgNCT03392974results2021-10-08Change of the Median Factor VIII (FVIII) Activity | Phase 3 | Completed | Biological: Valoctocogene Roxaparvovec | Hemophilia A | 1 | 2018-03-14 | 2019-05-22actual | — | 2023-10-03 |
| NVO | Novo Nordisk A/S | — | A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia ANCT03528551results2021-11-26Number of Adverse Events Reported | Phase 3 | Completed | Drug: Turoctocog alfa pegol, Turoctocog alfa pegol, Turoctocog alfa pegol | Congenital Bleeding Disorder, Haemophilia A | 160 | 2018-04-30 | 2020-12-03actual | — | 2022-12-22 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of AgeNCT00759655results2011-01-04Percentage of Participants With Factor VIII (FVIII) Inhibitor Development | Phase 3 | Terminatedsponsor's stated reason: See termination reason in detailed description. | Biological: Moroctocog alfa | Hemophilia A | 1 | Jun 2009 | Dec 2009actual | — | 2022-06-15 |
| NVO | Novo Nordisk A/S | — | A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)NCT03741881observationalThe number of treated bleeding episodes | — | Completed | Other: No treatment given | Haemophilia A, Haemophilia A With Inhibitors, Haemophilia B, Haemophilia B With Inhibitors | 231 | 2018-12-18 | 2021-10-25actual | — | 2021-11-23 |
| NVO | Novo Nordisk A/S | — | A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without InhibitorsNCT03196297results2021-05-10The Number of Bleeding Episodes During at Least 24 Weeks From Treatment Onset | Phase 2 | Completed | Drug: Concizumab, Turoctocog alfa | Haemostasis, Haemophilia A | 36 | 2017-08-16 | 2018-06-22actual | — | 2021-11-16 |
| NVO | Novo Nordisk A/S | — | To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in JapanNCT02207218observationalFrequency of Adverse Events (AEs) | — | Completed | Drug: turoctocog alfa | Congenital Bleeding Disorder, Haemophilia A | 40 | 2014-08-04 | 2020-11-10actual | — | 2021-11-15 |
| NVO | Novo Nordisk A/S | — | Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A PatientsNCT03179748observationalFrequency of adverse reactions | — | Completed | Drug: turoctocog alfa | Congenital Bleeding Disorder, Haemophilia A | 10 | 2018-06-20 | 2021-06-16actual | — | 2021-11-15 |
| NVO | Novo Nordisk A/S | — | A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With InhibitorsNCT03196284results2021-10-22The Number of Bleeding Episodes | Phase 2 | Completed | Drug: Concizumab, Eptacog alfa | Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors | 26 | 2017-08-10 | 2018-09-19actual | — | 2021-10-22 |
| PFE | Pfizer | $155.3B | PF-06741086 Long-term Treatment in Severe HemophiliaNCT03363321results2021-07-27Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) | Phase 2 | Completed | Biological: PF-06741086 | Hemophilia A or B | 20 | 2018-05-30 | 2020-08-05actual | — | 2021-07-27 |
| OPK | OPKO Health, Inc. | $1.0B | A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or BNCT02418793Composite safety and tolerability parameters as measured by adverse events, electrocardiograms (ECG), laboratory results, vital signs and injection site reactions | Phase 1 | Completed | Drug: MOD-5014 | Hemophilia A, Hemophilia B | 27 | May 2015 | Sep 2018actual | — | 2021-05-20 |
| PFE | Pfizer | $155.3B | Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A PatientsNCT04396639results2021-05-03Percentage of Participants Who Developed Factor VIII (FVIII) Inhibitors | Phase 4 | Completed | Biological: Moroctocog-alfa (AF-CC) | Hemophilia A | 50 | 2020-01-25 | 2020-09-24actual | — | 2021-05-03 |
| SNY | Sanofi | — | A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B PatientsNCT02035605The safety of ALN-AT3SC evaluated by the proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs), and AEs leading to study drug discontinuation. | Phase 1 | Completed | Drug: ALN-AT3SC, Sterile Normal Saline (0.9% NaCl) | Hemophilia A, Hemophilia B | 51 | 2014-01-20 | 2017-07-20actual | — | 2020-12-19 |
| NVO | Novo Nordisk A/S | — | Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia ANCT01493778results2018-10-30Incidence Rate of Factor VIII Inhibitors (Above or Equal to 0.6 BU (Bethesda Units)/mL) for the Main Phase of the Trial | Phase 3 | Completed | Drug: turoctocog alfa | Congenital Bleeding Disorder, Haemophilia A | 60 | 2012-09-17 | 2017-08-16actual | — | 2020-11-30 |
| NVO | Novo Nordisk A/S | — | Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia ANCT01480180results2020-04-20The Incidence Rate of FVIII-inhibitors ≥0.6 BU: After Approximately 19 Months | Phase 3 | Completed | Drug: turoctocog alfa pegol | Congenital Bleeding Disorder, Haemophilia A | 186 | 2012-01-30 | 2018-12-10actual | — | 2020-11-23 |
| NVO | Novo Nordisk A/S | — | A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia ANCT01731600results2019-10-30Number of Participants With Inhibitory Antibodies Against Coagulation Factor VIII (FVIII) ≥0.6 Bethesda Units | Phase 3 | Completed | Drug: turoctocog alfa pegol | Congenital Bleeding Disorder, Haemophilia A | 68 | 2013-02-20 | 2014-09-15actual | — | 2020-11-23 |
| PFE | Pfizer | $155.3B | Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine ProphylaxisNCT02718677observationalThe health-related quality of life in subjects treated with ReFacto AF routine prophylaxis | — | Withdrawnsponsor's stated reason: Company decision to not conduct study | Drug: Refacto AF | Hemophilia A | 0 | 2019-09-01 | 2021-05-01 | — | 2020-11-16 |
| NVO | Novo Nordisk A/S | — | Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.NCT01489111results2020-01-21Haemostatic Effect During Surgery Evaluated by the Four-point Scale, Assessed by the Investigator/Surgeon at the Day of Surgery - Four-point Response Scale: Excellent, Good, Moderate or None | Phase 3 | Completed | Drug: turoctocog alfa pegol | Congenital Bleeding Disorder, Haemophilia A | 36 | 2012-08-03 | 2018-12-10actual | — | 2020-08-10 |
| NVO | Novo Nordisk A/S | — | Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia ANCT02938585results2019-08-26Haemostatic Effect of Turoctocog Alfa (Treatment of Bleeds): 6 Months | Phase 3 | Completed | Drug: turoctocog alfa, turoctocog alfa | Congenital Bleeding Disorder, Haemophilia A | 68 | 2016-12-12 | 2018-03-16actual | — | 2020-07-27 |
| NVO | Novo Nordisk A/S | — | Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 TrialNCT03588741results2020-07-07Number of Adverse Events | Phase 3 | Terminatedsponsor's stated reason: The trial was terminated as the participant withdrew from the trial. | Drug: Turoctocog alfa | Haemophilia A | 1 | 2018-06-12 | 2019-06-19actual | — | 2020-07-07 |
| PTCT | PTC Therapeutics | $6.1B | Study of Ataluren (PTC124) in Hemophilia A and BNCT00947193results2020-06-16Number of Participants With a Plasma FVIII/FIX Activity Response at Day 14 | Phase 2 | Terminatedsponsor's stated reason: Study was terminated early due to Sponsor decision and not reflective of adverse safety findings. | Drug: Ataluren | Hemophilia A, Hemophilia B | 13 | 2009-10-14 | 2011-08-30actual | — | 2020-06-16 |
| NVO | Novo Nordisk A/S | — | Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia ANCT02035384observationalIncidence rate of FVIII inhibitors (at least 0.6 Bethesda Units (BU) for central laboratory analyses, or above the specific local laboratory reference range) represented as the percentage of patients developing inhibitors | — | Completed | Drug: turoctocog alfa | Congenital Bleeding Disorder, Haemophilia A | 69 | 2014-06-05 | 2020-01-15actual | — | 2020-04-27 |
| NVO | Novo Nordisk A/S | — | Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks PeriodNCT03449342results2020-03-18Occurrence of Confirmed FVIII Inhibitor Development (≥ 0.6 BU) | Phase 4 | Completed | Drug: turoctocog alfa | Congenital Bleeding Disorder, Haemophilia A | 60 | 2018-03-01 | 2019-03-25actual | — | 2020-04-17 |
| NVO | Novo Nordisk A/S | — | Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia ANCT02994407Number of adverse events | Phase 1 | Completed | Drug: turoctocog alfa pegol | Congenital Bleeding Disorder, Haemophilia A | 50 | 2017-01-30 | 2018-10-15actual | — | 2020-02-05 |
| PFE | Pfizer | $155.3B | PF-06741086 Multiple Dose Study in Severe HemophiliaNCT02974855results2019-12-04Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 2 | Completed | Biological: PF-06741086, PF-06741086, PF-06741086, PF-06741086 | Hemophilia A or B | 27 | 2017-03-08 | 2018-12-03actual | — | 2019-12-04 |
| NVO | Novo Nordisk A/S | — | A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With HemophiliaNCT03660774observationalCognition composite score according to the BAYLEY-III instrument | — | Completed | Other: No treatment given | Haemophilia A, Haemophilia B | 563 | 2018-09-27 | 2019-10-11actual | — | 2019-11-22 |
| PFE | Pfizer | $155.3B | Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care SettingNCT00950170results2019-07-19Percentage of Participants Who Developed Clinically Significant Factor VIII (FVIII) Inhibitors During the Course of the Study | Phase 4 | Completed | Procedure: Laboratory Tests | Hemophilia A | 23 | 2010-02-10 | 2016-11-24actual | — | 2019-07-19 |
| PFE | Pfizer | $155.3B | Understanding Hemophilia A and B Drug Dosage Administration PatternsNCT03248141results2019-05-20observationalResource Utilization Pattern | — | Terminatedsponsor's stated reason: Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on March 21, 2018. See details in Description section. | Drug: Hemophilia B standard half-life, Hemophilia B extended half-life, Hemophilia A standard half-life, Hemophilia A extended half-life | Hemophilia A, Hemophilia B | 11 | 2017-09-01 | 2018-03-14actual | — | 2019-05-20 |
| NVO | Novo Nordisk A/S | — | Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or BNCT01228669Number of adverse Events (AEs), including Serious Adverse Events (SAEs) | Phase 1 | Completed | Drug: NNC 0172-0000-2021, NNC 0172-0000-2021, placebo | Congenital Bleeding Disorder, Haemophilia A, Haemophilia B, Healthy | 52 | 2010-10-25 | 2012-09-10actual | — | 2019-05-15 |
| NVO | Novo Nordisk A/S | — | A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia SubjectsNCT01631942Number of adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: See detailed description | Drug: NNC172-2021 | Congenital Bleeding Disorder, Haemophilia A, Healthy | 4 | 2012-06-26 | 2012-09-04actual | — | 2019-05-15 |
| NVO | Novo Nordisk A/S | — | Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia ANCT02941354Plasma FVIII activity at 30 minutes(C30min) | Phase 1 | Completed | Drug: turoctocog alfa | Congenital Bleeding Disorder, Haemophilia A | 35 | 2016-10-10 | 2017-06-20actual | — | 2019-01-30 |
| PFE | Pfizer | $155.3B | Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIIINCT00543439results2019-01-11Mean Annualized Bleed Rate (ABR) by Treatment: On Demand Cohort | Phase 3 | Completed | Biological: Moroctocog alfa (AF-CC), Moroctocog alfa (AF-CC) | Hemophilia A | 66 | Dec 2007 | Apr 2018actual | — | 2019-01-11 |
| NVO | Novo Nordisk A/S | — | Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 TrialNCT02541942results2019-01-04Determination of HLA Type | Phase 2 | Completed | Other: No treatment given | Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors | 19 | 2015-04-03 | 2016-04-15actual | — | 2019-01-04 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Comparing Blood Levels of ReFacto and Advante in Hemophilia ANCT00168051Pharmacokinetic measurement of area under the plasma Factor VIII activity in plasma versus time curve for 48 hours. | Phase 4 | Withdrawn | Drug: ReFacto, Advante | Hemophilia A | 0 | Apr 2005 | Nov 2005actual | — | 2018-09-25 |
| PFE | Pfizer | $155.3B | Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGONCT01959919results2018-09-25observationalEase of Using Clotting Factor Treatment Score | — | Completed | Device: Refacto FusENGO | Hemophilia A | 86 | 2014-01-27 | 2016-12-12actual | — | 2018-09-25 |
| NVO | Novo Nordisk A/S | — | Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With InhibitorsNCT00951405Thrombogenecity | Phase 2 | Completed | Drug: activated recombinant human factor VII, long acting, activated recombinant human factor VII, long acting, activated recombinant human factor VII, long acting | Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors | 23 | 2009-09-01 | 2011-03-29actual | — | 2018-09-05 |
| PFE | Pfizer | $155.3B | Study Evaluating Pharmacovigilance Of Refacto AFNCT00895037results2018-07-17observationalNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | — | Completed | Drug: ReFacto AF (Moroctocog alfa) | Hemophilia A | 101 | 2009-07-17 | 2016-10-19actual | — | 2018-07-17 |
| NVO | Novo Nordisk A/S | — | A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia ANCT02920398Area under the FVIII activity-time curve | Phase 1 | Completed | Drug: turoctocog alfa pegol | Congenital Bleeding Disorder, Haemophilia A | 21 | 2016-10-04 | 2017-04-07actual | — | 2017-12-15 |
| NVO | Novo Nordisk A/S | — | Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015NCT00984126results2017-07-27Frequency of Development of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU)/mL) | Phase 3 | Completed | Drug: turoctocog alfa, turoctocog alfa | Congenital Bleeding Disorder, Haemophilia A | 214 | 2009-10-26 | 2016-06-28actual | — | 2017-07-27 |
| NVO | Novo Nordisk A/S | — | Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A SubjectsNCT02490787Number of adverse events (AEs) | Phase 1 | Completed | Drug: Concizumab, placebo | Congenital Bleeding Disorder, Haemophilia A | 24 | 2015-09-10 | 2016-10-14actual | — | 2017-07-21 |
| NVO | Novo Nordisk A/S | — | Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and InhibitorsNCT01392547results2013-12-06Effective Bleeding Control Defined as no Additional Haemostatic Medication (Other Than Trial Product) Given | Phase 3 | Completed | Drug: vatreptacog alfa (activated), eptacog alfa (activated) | Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors | 72 | Jul 2011 | Aug 2012actual | — | 2017-05-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Hemophilia A is matched — 7 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Haemophilia A
- Hemophilia A
- Haemophilia A With Inhibitors
- Hemophilia A or B
- Haemophilia A (Moderate or Severe)
- Haemophilia A With or Without Inhibitors
- Hemophilia A With Inhibitor
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Hemophilia A” (a text search, wider than this page)